Flurbiprofen transdermal - Tokuhon Corporation
Alternative Names: Fulruban Pap; Stayban® Pap; Yakuban TapeLatest Information Update: 12 Jan 2022
At a glance
- Originator Tokuhon Corporation
- Developer GC-Rise Pharmaceutical; Taisho Toyama Pharmaceutical; Tokuhon Corporation; Tokyo Medical and Dental University
- Class Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Propionic acids
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Inflammatory pain; Muscle pain; Musculoskeletal disorders; Osteoarthritis; Periarthritis; Tendinitis
- No development reported Pain
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for clinical-Phase-Unknown development in Osteoarthritis in Japan (PO)
- 09 Nov 2018 Taisho Toyama Pharmaceutical and Tokyo Medical and Dental University complete a clinical trial in Osteoarthritis in Japan (PO) (UMIN000024789)